Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer – Authors' reply

KEYNOTE-057 investigators

Research output: Contribution to journalArticleProfessionalpeer-review

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)e380
JournalThe Lancet Oncology
Issue number9
Publication statusPublished - 1 Sept 2021

Bibliographical note

Funding Information:
AVB reports research funding from AstraZeneca/MedImmune, Genentech/Roche, Merck Sharp & Dohme, and Seattle Genetics; has been a consultant to AstraZeneca/MedImmune, Cerulean Pharma, Genentech/Roche, Incyte, Merck Sharp & Dohme, Pfizer/EMD Serono, and Seattle Genetics/Astellas; and honoraria from AstraZeneca/MedImmune, Genentech/Roche, and Merck Sharp & Dohme. AMK reports research funding from FKD Industries and Merck Sharp & Dohme; honoraria from UroToday Publishing and EAU (EU Oncology); has been a consultant to Merck Sharp & Dohme, Bristol Myers Squibb, Imagin, Eisai, Arquer, MDX Health, Photocure, AstraZeneca, Tesaro, Abbott Molecular, US Biotest, Ferring, and BioClinica; travel expenses from Pfizer Japan; holds patents for CyPRIT-Cytokine Panel for Response to Intravesical Immunotherapy; and is the president of the International Bladder Cancer Group and the International Bladder Cancer Network. RdW reports research funding from Bayer and Sanofi; has been a consultant to Astellas, Merck Sharp & Dohme, Roche/Genentech, and Sanofi; and honoraria from Astellas, Bayer, Janssen, Merck Sharp & Dohme, Roche/Genentech, and Sanofi.

Cite this